Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer
Open Access
- 30 November 2018
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (70) , 39948-39956
Abstract
The metastasis of breast cancer is one of the main factors resulting in the high fatality of patients. Although many antagonists have been developed to inhibit the metastasis of breast cancer, their practical application has been limited because of the poor solubility of many chemotherapeutic drugs in the physiological environment. Herein, a complex of E5 peptide antagonist and acetylated PAMAM G5 (PAC80) has been constructed to enhance the solubility of the peptide antagonist. The E5 peptide antagonist has been designed and it was confirmed that it could specifically bind to CXCR4, which is a chemokine receptor involved in the metastasis of several types of cancers, in our previous work. The results demonstrated that PAC80 could significantly increase the solubility of the E5 peptide in the physiological environment, as well as the affinity of the E5 peptide to CXCR4-positive cell lines, and the inhibitory effect of the E5 peptide for cell migration in vitro. Meanwhile, the passive lung metastasis model of breast cancer was established and the anti-tumor metastasis of the PAC80–E5 complex was evaluated in vivo. The results show that the PAC80–E5 complex demonstrated excellent inhibition for the tumor metastasis at an E5 dosage of 10 and 20 mg kg−1. These effects indicate a feasible strategy to apply the PAC80–peptide complex in cancer therapies to improve the solubility and bioavailability.Keywords
Funding Information
- National Natural Science Foundation of China (21773042)
- Natural Science Foundation of Beijing Municipality (2162044)
This publication has 30 references indexed in Scilit:
- Agonists for the Chemokine Receptor CXCR4ACS Medicinal Chemistry Letters, 2011
- Novel peptide–dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancerInternational Journal of Nanomedicine, 2010
- Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug deliveryPeptides, 2010
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLBlood, 2009
- Discovery of Small Molecule CXCR4 AntagonistsJournal of Medicinal Chemistry, 2007
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activationExperimental Cell Research, 2005
- Poly(amidoamine) Dendrimer-Based Multifunctional Engineered Nanodevice for Cancer TherapyJournal of Medicinal Chemistry, 2005
- CXCL12–CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasionLaboratory Investigation, 2004
- CXCR4 Regulates Migration and Development of Human Acute Myelogenous Leukemia Stem Cells in Transplanted NOD/SCID MiceCancer Research, 2004